Infections caused by cytomegalovirus, particularly those that erupt during immunosuppression, have been a particular bugbear of transplant patients, but a new generation of anti-CMV agents are nearing the market, with Merck & Co. Inc.’s letermovir forging ahead in the latter stages of the race to market.
Letermovir is described as a first-in-class viral terminase complex inhibitor that unlike marketed CMV therapies is not a nucleoside derivative...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)